Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors

Clinical trial NCT02658214 · COMPLETED

Trial details

NCT number: NCT02658214
Sponsor: AstraZeneca
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

Small Cell Lung Carcinoma Carcinoma, Squamous Cell of Head and Neck Stomach Neoplasms Triple Negative Breast Neoplasms Ovarian Neoplasms Fallopian Tube Neoplasms Peritoneal Neoplasms Esophagogastric Junction Neoplasms Carcinoma, Pancreatic Ductal Esophageal Squamous Cell Carcinoma

Start date: 2016-04-28
Primary completion: 2019-11-14
Enrollment: 32

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.